Already a member?

PerkinElmer Launches SCID Test - Analyst Blog

PerkinElmer, Inc.
(
PKI
) announced the commercial launch of the EnLite Neonatal TREC
System screening test for Severe Combined Immunodeficiency (SCID)
that affects roughly 1 in 50,000 to 1 in 100,000 newborns every
year across the globe. Early detection of this disease caused by
genetic disorder is extremely important in order to avoid higher
costs and several complications due to late detection.

SCID reduces lifespan if not detected early. Its treatments
include bone marrow or cord blood transplant (BMT/CBT) from a
family member or donor.

The new screening test will save both time and costs in SCID
detection because it doesn't need all the steps in the workflow
required in the existing laboratory tests, thereby enhances
screening efficiency. The test will be introduced in select
countries in Europe and the Middle East under CE marking.

Recently, PerkinElmer also introduced the early onset
preeclampsia serum screening test, PreeclampsiaScreen T1, in the
U.S. The test would be useful in preventing preeclampsia, a
disease characterized by high blood pressure and high amounts of
protein in the urine of a pregnant woman, leading to delivery of
the fetus prior to 34 weeks' gestation.

Preeclampsia is a life threatening medical condition that affects
0.5% of all pregnancies, endangering the life of both pregnant
mother and the baby. It is a major contributor to maternal,
fetal, and neonatal morbidity and mortality.

For a long time, PerkinElmer is dedicated in offering products
and systems for prenatal clinical problems. Apart from the latest
offerings, PKI has offered non-invasive prenatal test based on
cell-free fetal DNA, and biochemical screening and SNP microarray
testing to detect birth defects and chromosome abnormalities.

In the second quarter of the year, this Zacks Rank #3 (Hold)
company posted adjusted earnings per share (EPS) of 51 cents,
beating the Zacks Consensus Estimate by 3 cents. However, the top
line lagged the year-ago earnings of 53 cents by nearly 4%.
Reported EPS fell 17.2% to 24 cents from 29 cents a year ago,
mainly due to significant rise in restructuring and contract
termination charges.

Revenues in the quarter rose 4.1% to $543.3 million, exceeding
the Zacks Consensus Estimate of $534 million. The increase was
driven by improvements in both of PKI's operating segments.

PerkinElmer expects organic revenues to increase in the
low-single digit range in the year compared with 2012. PKI also
expects reported earnings per share in the range of $1.40 to
$1.47 and adjusted earnings per share between $2.03 and $2.10
compared with the prior guidance of $2.00 to $2.10.

PerkinElmer, Inc. is a global technology company which provides
products and systems to the telecom, medical, pharmaceutical,
chemical, semiconductor and photographic markets. PKI has
operations in over 100 countries, and is a component of the
S&P 500 Index.

Currently, other stocks that are also performing well in the
medical products industry include
Alere Inc.
(
ALR
) and
PLC Systems Inc.
(
PLCSF
), both with a Zacks Rank #1 (Strong Buy), and
diaDexus, Inc.
(
DDXS
) with a Zacks Rank #2 (Buy).

Please note that once you make your selection, it will apply to all future visits to NASDAQ.com.
If, at any time, you are interested in reverting to our default settings, please select Default Setting above.

If you have any questions or encounter any issues in changing your default settings, please email isfeedback@nasdaq.com.

Please confirm your selection:

You have selected to change your default setting for the Quote Search. This will now be your default target page;
unless you change your configuration again, or you delete your
cookies. Are you sure you want to change your settings?